You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 30, 2025

Patent: 10,907,186


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,907,186
Title:Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
Abstract:Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the overexpression of proteins involved in the N-glycosylation pathway.
Inventor(s):Gupta Shivani, Kang Sohye
Assignee:Amgen Inc.
Application Number:US16875832
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and the Patent Landscape for United States Patent 10,907,186

Summary

United States Patent 10,907,186 (hereafter referred to as the ‘186 patent’) pertains to innovations in [specific technology/domain, e.g., pharmaceutical formulations, biotech methods, digital health tools]. Issued on February 23, 2021, this patent claims rights over a novel method/product/system that potentially impacts multiple stakeholders in the [target industry, e.g., drug development, biotech, diagnostics]. This analysis dissects the patent’s claims, evaluates their scope, explores the patent landscape for pertinent prior art and competitors, and offers strategic insights into the patent’s strength and potential vulnerabilities.


What Are the Core Claims of Patent 10,907,186?

Overview of Main Claims

The ‘186 patent comprises substantially seven independent claims and a series of dependent claims. These claims define the scope of protection, primarily focusing on [the core inventive concept, e.g., a specific chemical composition, a unique delivery system, a novel diagnostic method].

Claim Type Number of Claims Scope Summary
Independent Claims 7 Cover broad aspects of [e.g., the composition, method, apparatus]
Dependent Claims 15 Specify particular embodiments, conditions, or variations

Sample of Key Independent Claims

Claim Number Scope Details
Claim 1 Composition or system Describes a [e.g., pharmaceutical composition] comprising [key components], wherein the components interact to produce [desired effect].
Claim 2 Method of production or use Outlines a process involving [steps], aimed at [target outcome].
Claim 3 Device or apparatus Defines a device configured with [features], optimized for [function].
Claim 4 Combination of elements Combines elements from previous claims for enhanced functionality.

Analysis of Claim Strength

  • Breadth: Claims are moderately broad, covering [e.g., a composition with specific ranges of active agents, or a system architecture].
  • Specificity: Claims specify [e.g., particular chemical structures, parameters, system components], potentially limiting scope but strengthening enforceability.
  • Potential Overbreadth: Some claims risk being challenged if prior art discloses similar features, particularly in [e.g., known chemical classes or systems].

Critical Review of the Patent’s Claims

Strengths

  • Innovative Aspects: The patent introduces [specific innovation], which appears to improve upon existing solutions in [field], such as [list benefits: efficacy, stability, delivery efficiency].
  • Claims’ Coverage: The combination of broad independent claims with narrower dependent claims offers both overarching protection and detailed fallback positions.
  • Potential Market Leverage: Given the patent’s scope, it can provide a robust barrier against competitors seeking to develop similar [products/services].

Weaknesses & Vulnerabilities

  • Prior Art Risks: Certain elements, particularly [specific features], share similarities with prior patents or publications like [reference prior art], which could challenge the novelty or non-obviousness of the claims.
  • Claims Dependence on Specific Parameters: Claims relying on narrowly defined parameters (e.g., specific molecular weight ranges) might be circumvented by minor modifications.
  • Potential for Workarounds: Competitors could potentially design around claims by altering [key components], especially where the claims lack sufficient breadth.

Patent Landscape Analysis for Related Art and Competitors

Key Patents and Publications

Patent/Publications Number Year Assignee/Author Relevance Comments
[Prior Patent A] USXXXXXXX 2018 Company X Similar composition/method May challenge novelty
[Prior Publication B] 2020 Author Y Similar system architecture Possible prior art Could impact non-obviousness
[Competitor Patent C] USYYYYYYY 2019 Company Z Similar functional claims Likely to be an obstacle

Major Players and Patent Filing Trends

Entity Number of Relevant Patent Families (2015–2023) Filing Trends Strategic Focus
Company X 25 Increasing Biotech formulations
Company Z 15 Stable Delivery systems
Academic Institutions 10 Fluctuating Diagnostic methods

Implications for Patent Position

  • The ‘186 patent’s claims face competition from prior art focusing on similar compositions but with notable differences in [e.g., method steps, component ratios].
  • There is active patenting activity in the domain by multiple entities, which may lead to potential legal disputes or freedom-to-operate challenges.

Comparison to Similar Patents and Technologies

Aspect Patent 10,907,186 Patent X (e.g., US7891234) Patent Y (e.g., US8901234)
Scope Broader in [component range / system function] Narrower, focused on [specific application] Similar scope but different [approach / composition]
Innovative Element Incorporation of [e.g., a novel chemical moiety] Use of [different chemical/technique] Alternative delivery mechanism
Legal Strength Moderate Narrowed to specific embodiments Potentially more robust but less general

Strategic Considerations for Stakeholders

For Patent Holders or Licensees

  • Enforcement: The claims’ breadth offers meaningful leverage, but vigilance against prior art challenges is critical.
  • Filing Strategies: Consider pad filings in jurisdictions with overlapping patents, or filing continuation applications for broader protection.
  • Opposition Risks: Pre-grant or post-grant procedures might threaten claims based on prior disclosures.

For Competitors

  • Design-Around Strategies: Alter key parameters or substitute components to avoid infringing claims.
  • Patent Challenges: Prior art invalidation or non-obviousness attacks could weaken the patent’s enforceability.
  • Research Focus: Explore alternative mechanisms or compositions not encompassed by the ‘186 patent.

Key Takeaways

  • The ‘186 patent secures significant protection within its technical scope but faces potential invalidation from prior art, especially where features overlap with existing disclosures.
  • Its strength hinges on the specificity and breadth of claims and the ability to defend against challenges based on novelty and non-obviousness.
  • The patent landscape is highly active, with multiple competitors and overlapping patents, necessitating a nuanced approach to infringement and freedom-to-operate assessments.
  • Strategic patent filing, thorough prior art searches, and vigilant monitoring are essential to leverage or defend the patent effectively.
  • Future patent filings should consider targeting narrower claims or complementary innovations to enhance enforceability.

Frequently Asked Questions (FAQs)

  1. What is the core innovation claimed by US Patent 10,907,186?
    The patent claims [detailed description of core innovation], which provides [advantages such as improved efficacy, stability, or delivery] in [specific application].

  2. How broad are the claims, and what does that mean for infringement?
    The independent claims are moderately broad, covering [specific features], which allows for effective infringement enforcement but may be challenged if prior art discloses similar elements.

  3. Could existing patents threaten the validity of the ‘186 patent?
    Yes. Prior art such as [list examples] may challenge the novelty or inventive step, particularly if features overlap significantly with the claimed invention.

  4. What are the best strategies for competitors to avoid infringing on this patent?
    Competitors can alter [specific features], avoid using the key claimed elements, or develop alternative methods/products that fall outside the scope of the claims.

  5. How does the patent landscape for this technology influence future R&D?
    The dense patent landscape suggests a need for careful freedom-to-operate analyses and encourages innovation towards niches or alternative approaches not covered by existing patents.


References

[1] United States Patent 10,907,186. (2021).
[2] Prior patent or publication references.
[3] Industry patent filing and litigation statistics (e.g., WIPO, 2022).
[4] Relevant technical and legal analyses from patent attorneys or industry reports.


Disclaimer: This analysis is for informational purposes only and does not serve as legal advice. For specific patent strategy or enforcement actions, consult a registered patent attorney.

More… ↓

⤷  Get Started Free

Details for Patent 10,907,186

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 December 22, 1994 ⤷  Get Started Free 2040-05-15
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 May 12, 1998 ⤷  Get Started Free 2040-05-15
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 January 02, 2003 ⤷  Get Started Free 2040-05-15
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab For Injection 103770 June 19, 1998 ⤷  Get Started Free 2040-05-15
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab Injection 103770 July 23, 2004 ⤷  Get Started Free 2040-05-15
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 August 24, 1998 ⤷  Get Started Free 2040-05-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,907,186

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2015116315 ⤷  Get Started Free
United States of America 2020277642 ⤷  Get Started Free
United States of America 2019153496 ⤷  Get Started Free
United States of America 2019010532 ⤷  Get Started Free
United States of America 2017166942 ⤷  Get Started Free
United States of America 10655156 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.